Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: All that is gold does not glitter, not all those who wander are lost

Hepatology

Volumn 61, Issue 6, 2015, Pages 2104-2106

  Musso, Giovanni ^a  

^a GRADENIGO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OBETICHOLIC ACID; PROTEIN KINASE; RESVERATROL; S ADENOSYLMETHIONINE; SIRTUIN 1; 6-ETHYLCHENODEOXYCHOLIC ACID; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ARTICLE; BILE ACID METABOLISM; BIOLOGICAL ACTIVITY; CALORIC RESTRICTION; DIABETES MELLITUS; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVATION; FOLLOW UP; GLUCOSE INTOLERANCE; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; MEDICATION COMPLIANCE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGONISTS; ANALOGS AND DERIVATIVES; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHENODEOXYCHOLIC ACID; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STILBENES;

EID: 84929607068     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27772     Document Type: Article

References (5)

1. Neuschwander-Tetri B, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-965.
2. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2092-2103.
3. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 2014;34:837-843.
4. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612-622.
5. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62:1186-1195.